CDH
NWBO

Charles D. Hyman’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Charles D. Hyman’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-249,625
Closed -$87K – 154
2016
Q4 		$87K Hold
249,625
– – 0.01% 137
2016
Q3 		$135K Buy
249,625
+204,250
+450% +$93.4K 0.02% 135
2016
Q2 		$26K Hold
45,375
– – ﹤0.01% 141
2016
Q1 		$66K Hold
45,375
– – 0.01% 138
2015
Q4 		$145K Hold
45,375
– – 0.02% 136
2015
Q3 		$284K Buy
45,375
+12,000
+36% +$112K 0.05% 123
2015
Q2 		$331K Sell
33,375
-10,000
-23% -$87.6K 0.05% 123
2015
Q1 		$320K Buy
43,375
+2,000
+5% +$13.5K 0.05% 124
2014
Q4 		$221K Hold
41,375
– – 0.04% 129
2014
Q3 		$208K Hold
41,375
– – 0.03% 136
2014
Q2 		$278K Buy
41,375
+4,000
+11% +$25.5K 0.05% 125
2014
Q1 		$271K Sell
37,375
-2,000
-5% -$11.9K 0.05% 120
2013
Q4 		$148K Buy
39,375
+19,000
+93% +$73.5K 0.03% 134
2013
Q3 		$68K Hold
20,375
– – 0.01% 139
2013
Q2 		$68K Buy
+20,375
New +$73.9K 0.01% 135

Other funds holding NWBO

MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
WPP
Whalerock Point Partners Providence, Rhode Island $587M AUM 29.61% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Charles D. Hyman's NWBO Position: Q1 2017 in Review

Charles D. Hyman sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2017, closing a stake of 249,625 shares — an estimated $87K sold.

Charles D. Hyman first reported a position in NWBO in Q2 2013 and held it in 15 quarters. The position peaked at $331K in Q2 2015. 4 funds tracked by Wall St. Rank hold NWBO as of Q1 2017.

  • Charles D. Hyman reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2017 after selling out during the quarter.
  • Charles D. Hyman sold 249,625 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2017, an estimated $87K.
  • Charles D. Hyman first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 15 quarters.
  • Charles D. Hyman's Northwest Biotherapeutics, Inc. Common stock position peaked at $331K in Q2 2015.
  • 4 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2017.

Based on Charles D. Hyman's 13F filing for Q1 2017, filed 11 May 2017.